Author

M. Gruffaz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

C. Lu· 2 shared S.-J. Gao· 2 shared H. Liu· 1 shared H. Yuan· 1 shared J. S. Kim· 1 shared J. U. Jung· 1 shared K. Vasan· 1 shared Q. L. Michael· 1 shared

Activity by Year

2018-2019 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Lu

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CRISPR-Cas9 screening of KSHV-transformed cells identifies XPO1 as a vulnerable target of cancer cells

M. Gruffaz, H. Yuan, W. Meng, H. Liu, S. Bae, J. S. Kim, C. Lu, Y. Huang, S.-J. Gao

This study identifies XPO1 as a vulnerable target in cancer cells using CRISPR-Cas9 screening in KSHV-transformed cells, showing its role in cell proliferation and growth transformation.

bioRxiv · Apr 6, 2019Cancer Biology

Repurposing cytarabine for treating primary effusion lymphoma by targeting KSHV latent and lytic replications

M. Gruffaz, S. Zhou, K. Vasan, T. Rushing, Q. L. Michael, C. Lu, J. U. Jung, S.-J. Gao

This study identifies cytarabine as a potent inhibitor of KSHV-induced primary effusion lymphoma by targeting both viral and host DNA/RNA synthesis and inducing tumor regression in a xenograft model.

bioRxiv · Apr 11, 2018Microbiology